CB-AC-02
/ CHA Bio & Diostech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 08, 2024
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
(clinicaltrials.gov)
- P1/2 | N=24 | Active, not recruiting | Sponsor: CHABiotech CO., Ltd | Unknown status ➔ Active, not recruiting
Enrollment closed • Alzheimer's Disease • CNS Disorders • Transplantation
1 to 1
Of
1
Go to page
1